GenSight Biologics SA 2024 IR
The report outlines GenSight Biologics' financial and operational performance for the fiscal year ended December 31, 2024. Key highlights include the successful manufacture of the LUMEVOQ drug product batch, with over 100 vials available, and the submission of the updated regulatory file to the French medicines safety agency (ANSM) to prepare for the restart of the early access program. Additionally, the company reported positive long-term efficacy and safety results at four and five years post-treatment in the REFLECT Phase III clinical trial. Financially, the company completed several capital increases in 2024, raising significant gross proceeds, while continuing negotiations with creditors to extend loan maturities.
Company: GenSight Biologics SA
Sector: Professional & technical services
Country: France
Year: 2024
Type: IR
Pages: 352
Back to company
GenSight Biologics SA
Universal Registration Document
The report outlines GenSight Biologics' financial and operational performance for the fiscal year ended December 31, 2024. Key highlights include the successful manufacture of the LUMEVOQ drug product batch, with over 100 vials available, and the submission of the updated regulatory file to the French medicines safety agency (ANSM) to prepare for the restart of the early access program. Additionally, the company reported positive long-term efficacy and safety results at four and five years post-treatment in the REFLECT Phase III clinical trial. Financially, the company completed several capital increases in 2024, raising significant gross proceeds, while continuing negotiations with creditors to extend loan maturities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Apr 7, 2025
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees